Fax: (011) 30 (210) 683-9605
Infectious complications of monoclonal antibodies used in cancer therapy
A systematic review of the evidence from randomized controlled trials
Version of Record online: 11 APR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 11, pages 2182–2189, 1 June 2007
How to Cite
Rafailidis, P. I., Kakisi, O. K., Vardakas, K. and Falagas, M. E. (2007), Infectious complications of monoclonal antibodies used in cancer therapy. Cancer, 109: 2182–2189. doi: 10.1002/cncr.22666
- Issue online: 18 MAY 2007
- Version of Record online: 11 APR 2007
- Manuscript Accepted: 5 FEB 2007
- Manuscript Revised: 12 JAN 2007
- Manuscript Received: 13 NOV 2006
- 5CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5): 379–391., , , et al.
- 9Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 3725–3732., , , et al.
- 10Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005; 23: 1984–1992., , , et al.
- 12The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 3064–3071., , , et al.
- 15Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia(CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004; 18: 1093–1101., , , et al.
- 17Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23: 4265–4274., , , et al.
- 19Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676–3685., , , et al.